特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
953554

神経刺激デバイスの世界市場:2021-2030年

Global Neurostimulation Devices Market: Analysis and Forecast, 2021-2030

出版日: | 発行: BIS Research Inc. | ページ情報: 英文 266 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=106.59円
神経刺激デバイスの世界市場:2021-2030年
出版日: 2020年08月09日
発行: BIS Research Inc.
ページ情報: 英文 266 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の神経刺激デバイスの市場は2030年には180億3300万米ドルの規模に成長すると予測されています。パーキンソン病、アルツハイマー病、てんかん、神経障害性疼痛などの神経疾患の有病率の上昇などの要因が同市場の成長を推進しています。

当レポートでは、世界の神経刺激デバイスの市場を調査し、市場の定義と概要、COVID-19およびその他の市場影響因子の分析、関連法規制、製品パイプライン、市場規模の推移・予測、製品タイプ・用途・地域など各種区分別の内訳、競合環境、主要企業のプロファイルなどをまとめています。

第1章 製品の定義

第2章 調査範囲

第3章 調査手法

第4章 競合情勢

  • 主な展開・戦略
  • 市場シェア分析
  • 製品分析
  • 成長シェア分析

第5章 COVID-19の影響

第6章 産業分析

  • 規制の枠組み:地域別
  • 団体・コンソーシアム・協会
  • 特許分析
  • 製品パイプライン

第7章 世界の神経刺激装置市場

  • 市場概要
  • 神経刺激療法の進化
  • 市場シナリオ
  • 前提条件・制約
  • 市場力学
  • 影響分析
    • 成長推進因子
    • 成長抑制因子
    • 市場機会

第8章 市場分析・予測:製品タイプ別

  • 埋め込み型
    • 脊髄刺激デバイス
    • 聴覚脳幹インプラント
    • 深部脳刺激(DBS)
    • 迷走神経刺激(VNS)デバイス
    • 仙骨神経刺激(SNS)デバイス
    • 舌下神経刺激デバイス
    • その他
  • 非埋め込み型
    • 経頭蓋磁気刺激(TMS)
    • その他

第9章 市場分析・予測:用途別

  • 疼痛管理
  • 難聴
  • パーキンソン病
  • てんかん
  • 尿失禁・便失禁
  • うつ病
  • その他

第10章 市場分析・予測:地域・主要国別

  • 北米
  • 欧州
  • アジア太平洋
  • ラテンアメリカ
  • 中東・アフリカ

第11章 企業プロファイル

  • Abbott Laboratories
  • Axonics Modulation Technologies, Inc.
  • Beijing PINS Medical Co., Ltd.
  • Boston Scientific Corporation
  • Cochlear Ltd.
  • electroCore, Inc.
  • Helius Medical Technologies, Inc.
  • Inspire Medical Systems, Inc.
  • Laborie Medical Technologies, Inc.
  • LivaNova PLC
  • MED-EL
  • Medtronic Plc
  • NeuroMetrix, Inc.
  • NeuroPace, Inc.
  • Nevro Corporation
  • Sonova
  • Synapse Biomedical Inc.
  • The Magstim Company Limited
図表

List of Tables

  • Table 1: Mortality Due to Opioid-Use Disorders
  • Table 4.1: Product Analysis of Neurostimulation Devices
  • Table 5.1: Impact of COVID-19 on Treatment Landscape
  • Table 6.1: Global Neurostimulation Devices Market (Association/Consortium/Society)
  • Table 6.2: Product Pipeline Analysis of Neurostimulation Devices
  • Table 7.1: Some of the Recalled Neurostimulation Devices
  • Table 8.1: Specification of Different Spinal Cord Stimulation Device Offered by Different Companies
  • Table 10.1: Prevalence of Neurological Diseases in North America, 2014-2017
  • Table 10.2: Prevalence of Neurological Diseases in the U.S., 2014-2017
  • Table 10.3: Prevalence of Neurological Diseases in Canada, 2014-2017
  • Table 10.4: Prevalence of Neurological Diseases in Europe, 2014-2017
  • Table 10.5: Prevalence of Neurological Diseases in Germany, 2014-2017
  • Table 10.6: Prevalence of Neurological Diseases in the U.K., 2014-2017
  • Table 10.7: Prevalence of Neurological Diseases in France, 2014-2017
  • Table 10.8: Prevalence of Neurological Diseases in Italy, 2014-2017
  • Table 10.9: Prevalence of Neurological Diseases in Spain, 2014-2017
  • Table 10.10: Prevalence of Neurological Diseases in Russia, 2014-2017
  • Table 10.11: Prevalence of Neurological Diseases in Switzerland, 2014-2017
  • Table 10.12: Prevalence of Neurological Diseases in Asia-Pacific, 2014-2017
  • Table 10.13: Prevalence of Neurological Diseases in Japan, 2014-2017
  • Table 10.14: Prevalence of Neurological Diseases in China, 2014-2017
  • Table 10.15: Prevalence of Neurological Diseases in India, 2014-2017
  • Table 10.16: Prevalence of Neurological Diseases in Australia, 2014-2017
  • Table 10.17: Prevalence of Neurological Diseases in South Korea, 2014-2017
  • Table 10.18: Prevalence of Neurological Diseases in Latin America, 2014-2017
  • Table 10.19: Prevalence of Neurological Diseases in Brazil, 2014-2017
  • Table 10.20: Prevalence of Neurological Diseases in Mexico, 2014-2017
  • Table 10.21: Prevalence of Neurological Diseases in Argentina, 2014-2017

List of Figures

  • Figure 1: Percentage Share of Neurological Disorders Causing Global Deaths (2005, 2015, and 2030)
  • Figure 2: Global Neurostimulation Devices Market, 2019-2030
  • Figure 3: Growth Promoting and Growth Inhibiting Factors of Global Neurostimulation Devices Market
  • Figure 4: Global Neurostimulation Devices Market: Patent Analysis (by Year of Filing), January 2016-May 2020
  • Figure 5: Share of Key Developments and Strategies, January 2016-May 2020
  • Figure 6: Market Share Analysis for the Global Neurostimulation Devices Market (by Company), 2019
  • Figure 7: Global Neurostimulation Devices Market (by Product Type), 2019-2030
  • Figure 8: Global Neurostimulation Devices Market (by Application), 2019 and 2030
  • Figure 9: Global Neurostimulation Devices Market (by Region), 2019 and 2030
  • Figure 2.1: Global Neurostimulation Devices Market Segmentation
  • Figure 3.1: Global Neurostimulation Devices Market Research Methodology
  • Figure 3.2: Primary Research
  • Figure 3.3: Secondary Research
  • Figure 3.4: Shares of Key Company Profiles
  • Figure 3.5: Assumptions and Limitations
  • Figure 4.1: Share of Key Developments and Strategies (January 2016-May 2020)
  • Figure 4.2: Regulatory and Legal (by Company), January 2016-May 2020
  • Figure 4.3: Funding Activities and Investments (by Company), January 2016-May 2020
  • Figure 4.4: Partnerships, Alliances, Collaboration, and Business Expansions (by Company), January 2016-May 2020
  • Figure 4.5: New Offerings (by Company), January 2016-May 2020
  • Figure 4.6: Merger and Acquisition Activities (by Company), January 2016-May 2020
  • Figure 4.7: Market Share Analysis for the Global Neurostimulation Devices Market, (by Company), 2019
  • Figure 4.8: Market Share Analysis (by Company) for Global Spinal Cord Stimulation Devices Market, 2019
  • Figure 4.9: Market Share Analysis (by Company) for Global Deep Brain Stimulation Devices Market, 2019
  • Figure 4.10: Market Share Analysis (by Company) for Global Auditory Brainstem Implant Market, 2019
  • Figure 4.11: Growth Share Matrix for Global Neurostimulation Devices Market (by Product), 2019
  • Figure 5.1: COVID-19 Impact on the Global Elective Surgeries
  • Figure 5.2: Growth Trend of the Neurostimulation Devices
  • Figure 5.3: Global Neurostimulation Devices Market: Challenges and Opportunities
  • Figure 6.1: Global Neurostimulation Devices Market: Patent Analysis (by Year of Filing), January 2016-May 2020
  • Figure 7.1: Evolution of Neurostimulation Technologies
  • Figure 7.2: Global Neurostimulation Devices Market, 2019-2030
  • Figure 7.3: Market Dynamics
  • Figure 7.4: Impact Analysis of Market Drivers and Challenges
  • Figure 7.5: Number and Percentage of DALYs for Different Neurological Disorders, 2015
  • Figure 7.6: Number and Percentage of DALYs for Different Neurological Disorders, 2030
  • Figure 8.1: Segmentation of Global Neurostimulation Devices Market (by Product Type)
  • Figure 8.2: Global Neurostimulation Devices Market (by Product Type), 2019-2030
  • Figure 8.3: Segmentation of Implantable Neurostimulation Devices Market
  • Figure 8.4: Global Implantable Neurostimulation Devices Market, 2019-2030
  • Figure 8.5: Global Implantable Neurostimulation Devices Market, (by Product Type), 2019-2030
  • Figure 8.6: Mechanism Action of Spinal Cord Stimulation Device
  • Figure 8.7: Global Spinal Cord Stimulation Devices Market, (2019-2030)
  • Figure 8.8: Global Rechargeable Spinal Cord Stimulation (SCS) Devices Market, (2020-2030)
  • Figure 8.9: Global Non-Rechargeable Spinal Cord Stimulation Devices Market, (2019-2030)
  • Figure 8.10: Mechanism of Action of Auditory Brainstem Implants
  • Figure 8.11: Global Auditory Brainstem Implant Market, (2019-2030)
  • Figure 8.12: Global Deep Brain Stimulation Devices Market, (2019-2030)
  • Figure 8.13: Global Single-Channel Deep Brain Stimulation Devices Market, (2019-2030)
  • Figure 8.14: Global Dual-Channel Deep Brain Stimulation Devices Market, (2019-2030)
  • Figure 8.15: Global Vagus Nerve Stimulation Devices Market, (2019-2030)
  • Figure 8.16: Global Sacral Nerve Stimulation Devices Market, (2019-2030)
  • Figure 8.17: Global Hypoglossal Nerve Stimulation Devices Market, (2019-2030)
  • Figure 8.18: Others Implantable Neurostimulation Devices Market, (2019-2030)
  • Figure 8.19: Segmentation of Non-Implantable Neurostimulation Devices Market
  • Figure 8.20: Global Non-Implantable Neurostimulation Devices Market, (by Product Type), 2019-2030
  • Figure 8.21: Global Transcranial Magnetic Stimulation (TMS) Devices Market, (2019-2030)
  • Figure 8.22: Others Non-Implantable Neurostimulation Devices Market, (2019-2030)
  • Figure 9.1: Segmentation of Neurostimulation Devices Market (by Application)
  • Figure 9.2: Global Neurostimulation Devices Market (by Application), 2019-2030
  • Figure 9.3: Global Neurostimulation Devices Market (Pain Management), 2019-2030
  • Figure 9.4: Global Neurostimulation Devices Market (Hearing Loss), 2019-2030
  • Figure 9.5: Global Neurostimulation Devices Market (Parkinson's Disease), 2019-2030
  • Figure 9.6: Global Neurostimulation Devices Market (Epilepsy), 2019-2030
  • Figure 9.7: Global Neurostimulation Devices Market (Urinary and Fecal Incontinence), 2019-2030
  • Figure 9.8: Global Neurostimulation Devices Market (Depression), 2019-2030
  • Figure 9.9: Global Neurostimulation Devices Market (Other Applications), 2019-2030
  • Figure 10.1: Global Neurostimulation Devices Market (by Region), 2019 and 2030
  • Figure 10.2: North America Neurostimulation Devices Market, 2019-2030
  • Figure 10.3: North America Neurostimulation Devices Market: Market Dynamics
  • Figure 10.4: North America Neurostimulation Devices Market (by Product Type), 2019-2030
  • Figure 10.5: North America Implantable Neurostimulation Devices Market (by Type), 2019-2030
  • Figure 10.6: North America Neurostimulation Devices Market (by Country), 2019 and 2030
  • Figure 10.7: Alzheimer's Dementia in Different Age Groups in the U.S., 2019
  • Figure 10.8: U.S. Neurostimulation Devices Market, 2019-2030
  • Figure 10.9: Canada Neurostimulation Devices Market, 2019-2030
  • Figure 10.10: Europe Neurostimulation Devices Market, 2019-2030
  • Figure 10.11: Europe Neurostimulation Devices Market: Market Dynamics
  • Figure 10.12: Europe Neurostimulation Devices Market (by Product Type), 2019-2030
  • Figure 10.13: Europe Implantable Neurostimulation Devices Market (by Type), 2019-2030
  • Figure 10.14: Europe Neurostimulation Devices Market (by Country), 2019 and 2030
  • Figure 10.15: Germany Neurostimulation Devices Market, 2019-2030
  • Figure 10.16: U.K. Neurostimulation Devices Market, 2019-2030
  • Figure 10.17: France Neurostimulation Devices Market, 2019-2030
  • Figure 10.18: Italy Neurostimulation Devices Market, 2019-2030
  • Figure 10.19: Spain Neurostimulation Devices Market, 2019-2030
  • Figure 10.20: Russia Neurostimulation Devices Market, 2019-2030
  • Figure 10.21: Switzerland Neurostimulation Devices Market, 2019-2030
  • Figure 10.22: Rest-of-Europe Neurostimulation Devices Market, 2019-2030
  • Figure 10.23: Asia-Pacific Neurostimulation Devices Market, 2019-2030
  • Figure 10.24: Asia-Pacific Neurostimulation Devices Market: Market Dynamics
  • Figure 10.25: Asia-Pacific Neurostimulation Devices Market (by Product Type), 2019-2030
  • Figure 10.26: Asia-Pacific Implantable Neurostimulation Devices Market (by Type), 2019-2030
  • Figure 10.27: Asia-Pacific Neurostimulation Devices Market (by Country), 2019 and 2030
  • Figure 10.28: Japan Neurostimulation Devices Market, 2019-2030
  • Figure 10.29: China Neurostimulation Devices Market, 2019-2030
  • Figure 10.30: India Neurostimulation Devices Market, 2019-2030
  • Figure 10.31: Australia Neurostimulation Devices Market, 2019-2030
  • Figure 10.32: South Korea Neurostimulation Devices Market, 2019-2030
  • Figure 10.33: Rest-of-Asia-Pacific Neurostimulation Devices Market, 2019-2030
  • Figure 10.34: Latin America Neurostimulation Devices Market, 2019-2030
  • Figure 10.35: Latin-America Neurostimulation Devices Market: Market Dynamics
  • Figure 10.36: Latin America Neurostimulation Devices Market (by Product Type), 2019-2030
  • Figure 10.37: Latin America Implantable Neurostimulation Devices Market (by Type), 2019-2030
  • Figure 10.38: Latin America Neurostimulation Devices Market (by Country), 2019 and 2030
  • Figure 10.39: Brazil Neurostimulation Devices Market, 2019-2030
  • Figure 10.40: Mexico Neurostimulation Devices Market, 2019-2030
  • Figure 10.41: Argentina Neurostimulation Devices Market, 2019-2030
  • Figure 10.42: Rest-of-Latin America Neurostimulation Devices Market, 2019-2030
  • Figure 10.43: Middle East and Africa Neurostimulation Devices Market, 2019-2030
  • Figure 10.44: Middle East and Africa Neurostimulation Devices Market: Market Dynamics
  • Figure 10.45: Middle East and Africa Neurostimulation Devices Market (by Product Type), 2019-2030
  • Figure 10.46: Middle East and Africa Implantable Neurostimulation Devices Market (by Type), 2019-2030
  • Figure 11.1: Abbott Laboratories: Overall Product Portfolio
  • Figure 11.2: Abbott Laboratories: Overall Financials, 2017-2019
  • Figure 11.3: Abbott Laboratories: Revenue (by Product/Service), 2017-2019
  • Figure 11.4: Abbott Laboratories: Revenue (by Region), 2017-2019
  • Figure 11.5: Abbott Laboratories: R&D Expenditure, 2017-2019
  • Figure 11.6: Abbott Laboratories: SWOT Analysis
  • Figure 11.7: Axonics Modulation Technologies, Inc.: Overall Product Portfolio
  • Figure 11.8: Axonics Modulation Technologies, Inc.: Overall Financials, 2017-2019
  • Figure 11.9: Axonics Modulation Technologies, Inc.: R&D Expenditure, 2017-2019
  • Figure 11.10: Axonics Modulation Technologies, Inc.: SWOT Analysis
  • Figure 11.11: Beijing PINS Medical Co., Ltd.: Overall Product Portfolio
  • Figure 11.12: Beijing PINS Medical Co., Ltd.: SWOT Analysis
  • Figure 11.13: Boston Scientific Corporation: Overall Product Portfolio
  • Figure 11.14: Boston Scientific Corporation: Overall Financials, 2017-2019
  • Figure 11.15: Boston Scientific Corporation: Revenue (by Segment), 2017-2019
  • Figure 11.16: Boston Scientific Corporation: Revenue (by Sub-segment), 2017-2019
  • Figure 11.17: Boston Scientific Corporation: Revenue (by Region), 2017-2019
  • Figure 11.18: Boston Scientific Corporation: R&D Expenditure, 2017-2019
  • Figure 11.19: Boston Scientific Corporation: SWOT Analysis
  • Figure 11.20: Cochlear Ltd.: Overall Product Portfolio for Neurostimulation Devices Market
  • Figure 11.21: Cochlear Ltd.: Overall Financials, 2017-2019
  • Figure 11.22: Cochlear Ltd.: Revenue (by Segment), 2017-2019
  • Figure 11.23: Cochlear Ltd.: Revenue (by Region), 2017-2019
  • Figure 11.24: Cochlear Ltd.: R&D Expenditure
  • Figure 11.25: Cochlear Ltd.: SWOT Analysis
  • Figure 11.26: electroCore, Inc.: Overall Product Portfolio
  • Figure 11.27: electroCore, Inc.: Overall Financials, 2017-2019
  • Figure 11.28: electroCore, Inc.: Revenue (by Region), 2017-2019
  • Figure 11.29: electroCore, Inc.: R&D Expenditure, 2017-2019
  • Figure 11.30: electroCore, Inc.: SWOT Analysis
  • Figure 11.31: Helius Medical Technologies, Inc.: Overall Product Portfolio
  • Figure 11.32: Helius Medical Technologies, Inc.: Overall Financials, 2017-2019
  • Figure 11.33: Helius Medical Technologies, Inc.: R&D Expenditure, 2017-2019
  • Figure 11.34: Helius Medical Technologies, Inc.: SWOT Analysis
  • Figure 11.35: Inspire Medical System, Inc.: Overall Product Portfolio
  • Figure 11.36: Inspire Medical System, Inc.: Overall Financials, 2017-2019
  • Figure 11.37: Inspire Medical System, Inc.: Revenue (by Region), 2017-2019
  • Figure 11.38: Inspire Medical System, Inc.: R&D Expenditure, 2017-2019
  • Figure 11.39: Inspire Medical System Inc.: SWOT Analysis
  • Figure 11.40: Laborie Medical Technologies, Inc.: Overall Product Portfolio
  • Figure 11.41: Laborie Medical Technologies, Inc.: SWOT Analysis
  • Figure 11.42: LivaNova PLC: Overall Product Portfolio
  • Figure 11.43: LivaNova PLC: Overall Financials, 2017-2019
  • Figure 11.44: LivaNova PLC (by Segment), 2017-2019
  • Figure 11.45: LivaNova PLC: Revenue (by Region), 2017-2019
  • Figure 11.46: LivaNova PLC: R&D Expenditure, 2017-2019
  • Figure 11.47: LivaNova PLC: SWOT Analysis
  • Figure 11.48: MED-EL: Overall Product Portfolio
  • Figure 11.49: MED-EL: SWOT Analysis
  • Figure 11.50: Medtronic plc: Overall Product Portfolio
  • Figure 11.51: Medtronic Plc: Overall Financials, 2017-2019
  • Figure 11.52: Medtronic Plc: Revenue (by Segment), 2017-2019
  • Figure 11.53: Medtronic Plc: Revenue (by Region), 2017-2019
  • Figure 11.54: Medtronic Plc: Research and Development Expense, 2017-2019
  • Figure 11.55: Medtronic plc: SWOT Analysis
  • Figure 11.56: NeuroMetrix, Inc.: Overall Product Portfolio
  • Figure 11.57: NeuroMetrix, Inc.: Overall Financials, 2017-2019
  • Figure 11.58: NeuroMetrix, Inc.: R&D Expenditure, 2017-2019
  • Figure 11.59: NeuroMetrix, Inc.: SWOT Analysis
  • Figure 11.60: NeuroPace, Inc.: Overall Product Portfolio
  • Figure 11.61: NeuroPace, Inc.: SWOT Analysis
  • Figure 11.62: Nevro Corporation: Overall Product Portfolio
  • Figure 11.63: Nevro Corporation: Overall Financials, 2017-2019
  • Figure 11.64: Nevro Corporation: Revenue (by Region), 2017-2019
  • Figure 11.65: Nevro Corporation: R&D Expenditure, 2017-2019
  • Figure 11.66: Nevro Corporation: SWOT Analysis
  • Figure 11.67: Sonova: Overall Product Portfolio
  • Figure 11.68: Sonova: Overall Financials, 2017-2019
  • Figure 11.69: Sonova: Revenue (by Segment), 2017-2019
  • Figure 11.70: Sonova: Revenue (by Region), 2017-2019
  • Figure 11.71: Sonova: R&D Expenditure, 2017-2019
  • Figure 11.72: Sonova: SWOT Analysis
  • Figure 11.73: Synapse Biomedical Inc.: Overall Product Portfolio
  • Figure 11.74: Synapse Biomedical Inc.: SWOT Analysis
  • Figure 11.75: The Magstim Company Limited: Overall Product Portfolio
  • Figure 11.76: The Magstim Company Limited: SWOT Analysis
目次
Product Code: BHM0906SB

"Global Neurostimulation Devices Market to Reach $18,033.0 Million by 2030."

Market Report Coverage - Neurostimulation Devices

Market Segmentation

  • By Product Type: Implantable and non-implantable

Implantable neurostimulation devices can be further segmented into seven types - spinal cord stimulation, auditory brainstem implant, deep brain stimulation, vagus nerve stimulation, sacral nerve stimulation, hypoglossal nerve stimulation, and others.

Non-implantable neurostimulation devices can be further segmented into two types - transcranial magnetic stimulation, and others.

  • By Application: Pain management, hearing loss, Parkinson's disease, epilepsy, urinary and fecal Incontinence, depression, and others

Regional Segmentation

  • North America -U.S. and Canada
  • Europe - Germany, U.K., France, Italy, Spain, Russia, Switzerland, Rest-of-the-Europe
  • Asia-Pacific - Japan, China, India, Australia, South Korea, Rest-of-the-Asia-Pacific
  • Latin America- Brazil, Mexico, Argentina, and Rest-of-the-Latin America
  • Middle East and Africa

Growth Drivers

  • Growing incidence of neurological disorders
  • Increased side-effects of pain management medications in geriatric population
  • Limited success rate of drugs targeting specific diseases
  • Advent of sedentary lifestyles resulting massive burden of chronic pain
  • Growing concerns pertaining to pelvic health of geriatric population

Market Challenges

  • Financial burden of product recalls
  • Increased regulatory scrutiny
  • High cost of equipment

Market Opportunities

  • Evolution of biomarker-based therapeutics enabling early diagnostics of neurological disorders
  • Development of closed loop neuromodulation

Key Companies Profiled

Abbott Laboratories, Axonics Modulation Technologies, Inc., Beijing PINS Medical Co., Ltd., Boston Scientific Corporation, Cochlear Ltd., electroCore, Inc., Helius Medical Technologies, Inc., Inspire Medical Systems, Inc., Laborie Medical Technologies, Inc., LivaNova PLC, MED-EL, Medtronic plc, NeuroMetrix, Inc., NeuroPace, Inc., Nevro Corporation, Sonova, Synapse BioMedical, Inc., and The Magstim Company Limited

Key Questions Answered in this Report:

  • What is a neurostimulation device? How have different neurostimulation devices evolved over the years?
  • What are the advantages of non-invasive and minimally invasive neurostimulation devices?
  • What are the major market drivers, challenges, and opportunities in the global neurostimulation devices market?
  • What is the global neurostimulation devices market size in terms of revenue in 2020? What is the market size expected to be in 2030?
  • How is each segment of the global neurostimulation devices market expected to grow during the forecast period between 2021 to 2030, and what is the revenue expected to be generated by each of the segments by the end of 2030?
  • What are the developmental strategies implemented by the key players to sustain in the competitive market?
  • What is the growth potential of the neurostimulation devices market in each region, namely, North America, Europe, Asia-Pacific, and the Rest-of-the-World?
  • Which type of neurostimulation devices are expected to dominate the market in 2030, and why?
  • Which key players of the neurostimulation devices market are expected to grow during the forecast period?
  • Which neurostimulation technology is leading the market in 2019 and expected to dominate the market in 2030, and why?
  • Which applications are leading the neurostimulation devices market in 2019 and are expected to dominate the market in 2030, and why?
  • Which region dominated the global neurostimulation devices market in 2019 and what are the expected trends from each of the regions in the forecast period 2021-2030?
  • What is the impact of COVID-19 on the neurostimulation devices market?
  • What type of products coming in the upcoming years pertaining to neurostimulation devices?

Market Overview

Neurostimulation devices consider the implantable and non-implantable neurostimulation devices which act on the spinal cord and brain to deliver the electrical stimulation to a targeted area. These types of devices are mainly used in the treatment and management of Parkinson's disease, bowel and bladder dysfunction, Alzheimer's disease, and relieving chronic pain of the body. For carrying out innovative research in the field of neurostimulation devices, companies in the market received funding and investments by a few government organizations. The global neurostimulation devices market witnessed approximately 22 funding and investments in the past four years (January 2016-May 2020). For instance, NeuroPace, Inc. received $74 million funding from KCK Group and OrbiMed Advisors for ramping the production of NeuroPace RNS System, which was approved by the FDA in 2013. This device is used for the treatment and management of epileptic seizures.

The companies received a large number of product approvals by the regulatory bodies, including FDA, PMDA, Japan's Ministry of Health, Labour and Welfare, CE mark certification, European Medical Device Regulation (MDR) certification, and TGA approvals. Medtronic plc, Helius Medical Technologies, BrainsWay, Nevro Corporation, and Cochlear Ltd. received the maximum number of product approvals. For instance, in January 2020, Medtronic plc received CE mark approval for the Percept PC neurostimulator DBS system with BrainSense Technology. This device is used for the treatment of Parkinson's disease. Moreover., in March 2020, Helius Medical Technologies received approval from Health Canada to commercialize the PoNS Device. This device is used for the treatment and management of multiple sclerosis (MS).

The market is favored by multiple factors, which include rising prevalence of neurological diseases, such as Parkinson's disease, Alzheimer's disease, epilepsy, and neuropathic pain. Neurostimulation devices have shown promising results to cure disorders that affect the activity of the nervous system that includes the brain and spinal cord. Furthermore, there are plenty of options available in the neurostimulation devices market offering preventive treatment against such conditions. Such products are therefore being adopted even by professionals and by people of different age groups. Hence, the results of the prevention and treatment of different neurological disorders are accelerating the growth of the neurostimulation devices market.

Elderly population is mostly under pain management treatment for different neurological disorders, which include Parkinson's disease and Alzheimer's disease. As in the geriatric population, they are likely to have an increased risk of adverse reactions from pharmacological methods which are used for pain management medications. Thus, such methods that are used for the treatment of neurostimulation disorders consist of minimally invasive methods used for the management of persistent pain and cause no side effects and risk. Addressing chronic diseases that have a high incidence in the geriatric population is expected to gain momentum due to this growing number and shall continue to drive the global neurostimulation devices market.

All these factors are thus, expected to contribute to market growth during the forecast period.

Within the research report, the market is segmented based on product type, application, and region, which highlight value propositions and business models useful for industry leaders and stakeholders. The research also comprises country-level analysis, go-to-market strategies of leading players, future opportunities, among others, to provide a 360-coverage of the domain.

Competitive Landscape

Major players, including Medtronic plc, Boston Scientific Corporation, Cochlear, Ltd., and Abbott Laboratories, among others, led the number of synergistic developments (partnerships and alliances) witnessed by the market. Based on the region, North America is expected to retain a leading position in the market throughout the forecast period 2021-2030, followed by Europe. North America's market dominance, as well as the market growth in the region, can primarily be attributed to the presence of several established leading players including Abbott Laboratories, Boston Scientific Corporation, Inspire Medical Systems, Inc., Nuvectra Corporation, NeuroMetrix, Inc., among others that make the region one of the attractive markets for neurostimulation devices. These players have entered into strategic partnerships with the leading research centers and universities, and government medical research centers in the region to facilitate the development of their products. For instance, in May 2019, Abbott Laboratories partnered with NIH on the BRAIN (Brain Research through Advancing Innovative Neurotechnologies) initiative to accelerate advancements in neurological science. Likewise, in January 2018, Helius Medical Technologies, Inc. partnered with Key Tronic corporation to provided contract manufacturing for portable neuromodulation stimulator (PoNS) devices.

Table of Contents

1 Product Definition

2 Research Scope

  • 2.1 Scope of Study
  • 2.2 Inclusion and Exclusion Criteria of the Report
    • 2.2.1 Inclusion Criteria
    • 2.2.2 Exclusion Criteria of the Report
  • 2.3 Key Questions Answered in the Report

3 Report Methodology

  • 3.1 Primary Data Sources
  • 3.2 Secondary Data Sources
  • 3.3 Data Sources Categorization
  • 3.4 Selection Criteria for Company Profiles
  • 3.5 Assumptions and Limitations

4 Competitive Landscape

  • 4.1 Key Developments and Strategies
    • 4.1.1 Regulatory and Legal Landscape
    • 4.1.2 Funding Activities and Investments
    • 4.1.3 Partnerships, Collaborations, Alliances, and Business Expansions
    • 4.1.4 New Offerings
    • 4.1.5 Mergers and Acquisition Activities
  • 4.2 Market Share Analysis
    • 4.2.1 Market Share Analysis (by Company)
    • 4.2.2 Market Share Analysis for Global Spinal Cord Stimulation Devices Market, 2019
    • 4.2.3 Market Share Analysis for Global Deep Brain Stimulation Devices Market, 2019
    • 4.2.4 Market Share Analysis for Global Auditory Brainstem Implant Market, 2019
  • 4.3 Product Analysis
  • 4.4 Growth Share Analysis

5 Impact of COVID-19 on Neurostimulation Devices Market

  • 5.1 Impact on Global Treatment Landscape
  • 5.2 Impact on Adoption Rate of Neurostimulation Devices
  • 5.3 Impact on Global Market Size
  • 5.4 Entry Barriers and Opportunities for the Companies in Global Neurostimulation Devices Market

6 Industry Analysis

  • 6.1 Regulatory Framework
    • 6.1.1 Regulations in North America
      • 6.1.1.1 U.S.
      • 6.1.1.2 Canada
    • 6.1.2 Regulations in Europe
    • 6.1.3 Regulations in Asia-Pacific
      • 6.1.3.1 National Medical Products Administration (NMPA)
      • 6.1.3.2 Pharmaceutical and Medical Device Agency (PMDA)
      • 6.1.3.3 Therapeutic Goods Administration (TGA)
  • 6.2 Societies, Consortium, and Associations for Global Neurostimulation Devices Market
  • 6.3 Patent Analysis
  • 6.4 Product Pipeline

7 Global Neurostimulation Devices Market

  • 7.1 Market Overview
  • 7.2 Evolution of the Neurostimulation Therapy
  • 7.3 Global Market Scenario
  • 7.4 Assumptions and Limitations
  • 7.5 Market Dynamics
  • 7.6 Impact Analysis
    • 7.6.1 Market Drivers
      • 7.6.1.1 Growing Incidence of Neurological Disorders
      • 7.6.1.2 Increased Side-Effects of Pain Management Medications in Geriatric Population
      • 7.6.1.3 Limited Success Rate of Drugs Targeting Specific Disease
      • 7.6.1.4 Advent of Sedentary Lifestyles Resulting in Massive Burden of Chronic Pain
      • 7.6.1.5 Growing Concerns Pertaining to Pelvic Health of Geriatric Population
    • 7.6.2 Market Restraints
      • 7.6.2.1 Financial Burden of Product Recalls
      • 7.6.2.2 Increased Regulatory Scrutiny
      • 7.6.2.3 High Cost of Equipment
    • 7.6.3 Market Opportunities
      • 7.6.3.1 Evolution of Biomarker-Based Therapeutics Enabling Early Diagnostics of Neurological Disorders
      • 7.6.3.2 Development of Closed Loop Neuromodulation

8 Global Neurostimulation Devices (by Product Type)

  • 8.1 Implantable Neurostimulation Devices
    • 8.1.1 Spinal Cord Stimulation Devices
      • 8.1.1.1 Rechargeable Spinal Cord Stimulation
      • 8.1.1.2 Non-Rechargeable Spinal Cord Stimulation
    • 8.1.2 Auditory Brainstem Implant
    • 8.1.3 Deep Brain Stimulation (DBS)
      • 8.1.3.1 Single Channel DBS
      • 8.1.3.2 Dual Channel DBS
    • 8.1.4 Vagus Nerve Stimulation (VNS) Devices
    • 8.1.5 Sacral Nerve Stimulation (SNS) Devices
    • 8.1.6 Hypoglossal Nerve Stimulation Devices
    • 8.1.7 Others Implantable Neurostimulation Devices
  • 8.2 Non-Implantable Neurostimulation Devices
    • 8.2.1 Transcranial Magnetic Stimulation (TMS)
    • 8.2.2 Others Non-Implantable Neurostimulation Device

9 Global Neurostimulation Devices Market (by Application)

  • 9.1 Pain Management
  • 9.2 Hearing Loss
  • 9.3 Parkinson's Disease
  • 9.4 Epilepsy
  • 9.5 Urinary and Fecal Incontinence
  • 9.6 Depression
  • 9.7 Other Applications

10 Global Neurostimulation Devices Market (by Region)

  • 10.1 North America
    • 10.1.1 North America Neurostimulation Devices Market (by Product Type)
      • 10.1.1.1 North America Implantable Neurostimulation Devices Market (by Type)
    • 10.1.2 North America Neurostimulation Devices Market (by Country)
      • 10.1.2.1 U.S.
      • 10.1.2.2 Canada
  • 10.2 Europe
    • 10.2.1 Europe Neurostimulation Devices Market (by Product Type)
      • 10.2.1.1 Europe Implantable Neurostimulation Devices Market (by Type)
    • 10.2.2 Europe Neurostimulation Devices Market (by Country)
      • 10.2.2.1 Germany
      • 10.2.2.2 U.K.
      • 10.2.2.3 France
      • 10.2.2.4 Italy
      • 10.2.2.5 Spain
      • 10.2.2.6 Russia
      • 10.2.2.7 Switzerland
      • 10.2.2.8 Rest-of-Europe
  • 10.3 Asia-Pacific
    • 10.3.1 Asia-Pacific Neurostimulation Devices Market (by Product Type)
      • 10.3.1.1 Asia-Pacific Implantable Neurostimulation Devices Market (by Type)
    • 10.3.2 Asia-Pacific Neurostimulation Devices Market (by Country)
      • 10.3.2.1 Japan
      • 10.3.2.2 China
      • 10.3.2.3 India
      • 10.3.2.4 Australia
      • 10.3.2.5 South Korea
      • 10.3.2.6 Rest-of-Asia-Pacific
  • 10.4 Latin America
    • 10.4.1 Latin America Neurostimulation Devices Market (by Product Type)
      • 10.4.1.1 Latin America Implantable Neurostimulation Devices Market (by Type)
    • 10.4.2 Latin America Neurostimulation Devices Market (by Country)
      • 10.4.2.1 Brazil
      • 10.4.2.2 Mexico
      • 10.4.2.3 Argentina
      • 10.4.2.4 Rest-of-Latin America
    • 10.4.3 Middle East and Africa (MEA)
    • 10.4.4 Middle East and Africa Neurostimulation Devices Market (by Product Type)
    • 10.4.5 Middle East and Africa Implantable Neurostimulation Devices Market (by Type)

11 Company Profiles

  • 11.1 Abbott Laboratories
    • 11.1.1 Company Overview
    • 11.1.2 Role of Abbott Laboratories in the Neurostimulation Device Market
    • 11.1.3 Financials
    • 11.1.4 SWOT Analysis
  • 11.2 Axonics Modulation Technologies, Inc.
    • 11.2.1 Company Overview
    • 11.2.2 Role of Axonics Modulation Technologies, Inc. in the Neurostimulation Devices Market
    • 11.2.3 Financials
    • 11.2.4 SWOT Analysis
  • 11.3 Beijing PINS Medical Co., Ltd.
    • 11.3.1 Company Overview
    • 11.3.2 Role of Beijing PINS Medical Co., Ltd. in the Neurostimulation Devices Market
    • 11.3.3 SWOT Analysis
  • 11.4 Boston Scientific Corporation
    • 11.4.1 Company Overview
    • 11.4.2 Role of Boston Scientific Corporation in the Neurostimulation Devices Market
    • 11.4.3 Financials
    • 11.4.4 SWOT Analysis
  • 11.5 Cochlear Ltd.
    • 11.5.1 Company Overview
    • 11.5.2 Role of Cochlear Ltd. in the Neurostimulation Devices Market
    • 11.5.3 Financials
    • 11.5.4 SWOT Analysis
  • 11.6 electroCore, Inc.
    • 11.6.1 Company Overview
    • 11.6.2 Role of electroCore, Inc. in the Neurostimulation Devices Market
    • 11.6.3 Financials
    • 11.6.4 SWOT Analysis
  • 11.7 Helius Medical Technologies, Inc.
    • 11.7.1 Company Overview
    • 11.7.2 Helius Medical Technologies, Inc. in the Neurostimulation Devices Market
    • 11.7.3 Financials
    • 11.7.4 SWOT Analysis
  • 11.8 Inspire Medical Systems, Inc.
    • 11.8.1 Company Overview
    • 11.8.2 Role of Inspire Medical System, Inc. in the Neurostimulation Devices Market
    • 11.8.3 Financials
    • 11.8.4 SWOT Analysis
  • 11.9 Laborie Medical Technologies, Inc.
    • 11.9.1 Company Overview
    • 11.9.2 Role of Laborie Medical Technologies, Inc. in the Neurostimulation Devices Market
    • 11.9.3 SWOT Analysis
  • 11.1 LivaNova PLC
    • 11.10.1 Company Overview
    • 11.10.2 Role of LivaNova PLC in the Neurostimulation Devices Market
    • 11.10.3 Financials
    • 11.10.4 SWOT Analysis
  • 11.11 MED-EL
    • 11.11.1 Company Overview
    • 11.11.2 Role of MED-EL in the Neurostimulation Devices Market
    • 11.11.3 SWOT Analysis
  • 11.12 Medtronic Plc
    • 11.12.1 Company Overview
    • 11.12.2 Role of Medtronic plc in the Neurostimulation Devices Market
    • 11.12.3 Financials
    • 11.12.4 SWOT Analysis
  • 11.13 NeuroMetrix, Inc.
    • 11.13.1 Company Overview
    • 11.13.2 Role of NeuroMetrix, Inc. in the Neurostimulation Devices Market
    • 11.13.3 Financials
    • 11.13.4 SWOT Analysis
  • 11.14 NeuroPace, Inc.
    • 11.14.1 Company Overview
    • 11.14.2 Role of NeuroPace, Inc. in the Neurostimulation Devices Market
    • 11.14.3 SWOT Analysis
  • 11.15 Nevro Corporation
    • 11.15.1 Company Overview
    • 11.15.2 Role of Nevro Corporation in the Neurostimulation Devices Market
    • 11.15.3 Financials
    • 11.15.4 SWOT Analysis
  • 11.16 Sonova
    • 11.16.1 Company Overview
    • 11.16.2 Role of Sonova in the Neurostimulation Devices Market
    • 11.16.3 Financials
    • 11.16.4 SWOT Analysis
  • 11.17 Synapse Biomedical Inc.
    • 11.17.1 Company Overview
    • 11.17.2 Role of Synapse Biomedical Inc. in the Neurostimulation Devices Market
    • 11.17.3 SWOT Analysis
  • 11.18 The Magstim Company Limited
    • 11.18.1 Company Overview
    • 11.18.2 Role of The Magstim Company Limited in the Neurostimulation Devices Market
    • 11.18.3 SWOT Analysis
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.